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ABSTRACT
New treatments based on combinations of standard therapeutic modalities and immunotherapy are of
potential use, but require a profound understanding of immune modulatory properties of standard
therapies. Here, the impact of standard (chemo)radiotherapy on the immune system of cervical cancer
patients was evaluated. Thirty patients with cervical cancer were treated with external beam radiation
therapy (EBRT), using conventional three-dimensional or intensity modulated radiation therapy without
constraints for bone marrow sparing. Serial blood sampling for immunomonitoring was performed before,
midway and at 3, 6 and 9 weeks after EBRT to analyze the composition of lymphocyte and myeloid-cell
populations, the expression of co-stimulatory molecules, T-cell reactivity and antigen presenting cell (APC)
function. Therapy significantly decreased the absolute numbers of circulating leukocytes and
lymphocytes. Furthermore, the capacity of the remaining T cells to respond to antigenic or mitogenic
stimulation was impaired. During treatment the frequency of both CD4C and CD8C T cells dropped and
CD4C T cells displayed an increased expression of programmed cell death-1 (PD-1). In vitro blocking of PD-1
successfully increased T-cell reactivity in all five samples isolated before radiotherapy but was less successful
in restoring reactivity in samples isolated at later time points. Moreover, (chemo)radiotherapy was associated
with an increase in both circulating monocytes and myeloid-derived suppressor cells (MDSCs) and an
impaired capacity of APCs to stimulate allogeneic T cells. T-cell reactivity was slowly restored at 6–9 weeks
after cessation of therapy. We conclude that conventional (chemo)radiotherapy profoundly suppresses the







Radiotherapy is used as primary or adjuvant therapy in the cura-
tive treatment of patients with cervical cancer. Primary (chemo)
radiotherapy is an effective treatment for locally advanced cervi-
cal cancer with a 5-y pelvic control rate of 87% and a cancer-
specific survival of 79%.1 However, especially in cases with tumor
cell positive lymph nodes and patients with higher stages, sys-
temic failure of current therapies represents a major challenge.
Radiotherapy was thought to mediate its effect through direct
cytotoxic or cytostatic effects on malignant cells, but (pre)clinical
findings suggest that its therapeutic effect also contains vascular
and immunogenic components. Normalization of the vasculature
by radiotherapy facilitates the delivery of chemotherapeutic com-
pounds and promotes the infiltration by effector immune cells
into the tumor bed.2-4 In addition, radiation therapy may allevi-
ate immune suppression in the tumor microenvironment5-7 as
well as (re)activate a tumor-specific cellular immune response.6
Changes in the tumor microenvironment contribute substantially
to treatment success or failure, particularly in so-called
immunogenic tumors.8 Interestingly, it was shown that a pre-
treatment peripheral blood lymphocyte count at or above the
median value was associated with higher clinical responses and
survival rates. Apparently, peripheral blood lymphocyte count
and lymphocyte subsets are independent predictors of survival
and tumor regression in cervical cancer patients treated with
concurrent chemoradiation.9,10
Cervical cancer is regarded as an immunogenic tumor since
it is induced by a persistent infection with human papilloma
virus (HPV), most often HPV16 or HPV18.11 The number and
functional orientation of tumor-infiltrating CD4C and CD8C T
cells and the presence of M1 type macrophages are strongly
associated with survival in patients with cervical cancer after
primary treatment.12-15 The upregulation of signaling through
negative co-stimulatory molecules on T cells, such as Cytotoxic
T-lymphocyte Antigen 4 (CTLA-4) and programmed cell
death-1 (PD-1), is another mechanism through which T-cell
infiltration and function can be impaired in cervical cancer.16,17
Whereas studies in mouse tumor models suggest that certain
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radiotherapy schedules can be combined with immunother-
apy,18-20 the effect of standard radiation therapy in patients
with cervical cancer has not been extensively studied. Most
clinical studies investigated the baseline lymphocyte count as a
prognostic predictor of treatment response,9,10,21,22 rather than
the effects of therapy on the composition and function of these
cells during treatment. Therefore, this study focused on the
influence of pelvic radiation on immune responses in patients
with cervical cancer during and after treatment. We prospec-
tively analyzed changes in the immune cell composition and
function during radiation therapy, with or without concomitant
platinum-based chemotherapy, in serial blood samples from 30
patients with cervical cancer. We examined alterations in dif-
ferent lymphocytes subtypes, myeloid cell populations, the
expression of co-stimulatory molecules, T-cell reactivity to
antigens and the capacity of antigen presenting cells (APCs) to
stimulate T cells. Our study showed that (chemo)radiotherapy
for cervical cancer induced unfavorable immune changes
reflected by a decreased number of circulating lymphocytes
and an increased percentage in myeloid-cell populations,
including myeloid-derived suppressor cells (MDSCs) and
monocytes. Moreover, radiotherapy subverted the reactivity of
T cells to antigenic stimulation and the capacity of APCs to
enhance allogeneic T-cell proliferation. We further demon-
strated that radiotherapy upregulates PD-1 expression on the
circulating CD4C T cells, which can partially explain their
lower reactivity to antigenic stimulation.
Results
Characteristics of the patients
Thirty patients with histologically proven invasive cervical can-
cer FIGO stage IB1 to IV, who were to receive EBRT with a
curative intention, were enrolled between October 2011 and
December 2014. A detailed treatment schedule is shown in
Fig. 1. Patient characteristics are summarized in Table 1.
Twenty-three patients (76.6%) received combined radiotherapy
and chemotherapy, of which 18 with brachytherapy and 5 with-
out. Four patients (13.3%) received radiotherapy alone, two
patients (6.7%) received radiotherapy with brachytherapy and
1 patient (3.3%) received radiotherapy with hyperthermia. The
patient receiving hyperthermia was initially scheduled for
radiotherapy in combination with chemotherapy, but chemo-
therapy was canceled due to pre-existent renal impairment.
Table S1 shows detailed information about all participating
patients including treatment indication, dosages of the different
treatment regimens and existence of high or low tumor load
(high in case of primary or recurrence therapy; low in case of
adjuvant, post-operative therapy). Three patients refused fur-
ther participation after the first blood sampling and were con-
sidered as lost to immunological follow-up.
Radiation therapy has a profound effect on circulating
immune cells
The routine leukocyte differential count obtained daily during
the first week of EBRT, after 15 fractions of EBRT, and 3 weeks
after completion of EBRT in the first 18 patients showed a
decreased number of leucocytes in blood, which included a
decrease in the absolute number of lymphocytes. This decrease
in lymphocytes occurred early during treatment; already within
48 h after the first fraction a decrease of 27% was observed
(from 1.916 £ 109/L (mean, range 0.96–3.37) at baseline to
1.397 £ 109/L (mean, range 0.5–1.99) after the second fraction;
p D 0.0004) (Fig. 2A), and lasted at least until 3 weeks after
completion of (chemo)radiation therapy (Fig. 2B). It was
Figure 1. Treatment and blood sampling schedule. Blood samples 1–5: blood samples for immunomonitoring. Numbers above the blood samples indicate the amount of
patients who provided blood for immunomonitoring. Abbreviations: EBRTD external beam radiation therapy; ChThD chemotherapy; BT D brachytherapy.
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therefore decided to extend the observation period. An
extended follow up of 6 weeks after completion of EBRT was
done in 12 patients, and follow-up of 9 weeks after completion
of EBRT was possible in 10 patients. All 30 patients showed the
most distinct decrease of peripheral lymphocytes halfway the
radiation treatment (after 15 fractions) with a mean absolute
lymphocyte count of 0.39 £ 109/L, and showed a slight increase
of lymphocyte count when radiation treatment was finished
(Fig. 2B). Although at 6 weeks after completion of radiother-
apy, the lymphocyte count was slightly increased compared to
mid-treatment, it was still significantly lower when compared
to baseline (p < 0.0001). This decrease in lymphocytes
occurred regardless of tumor-load and of concurrent cisplatin
treatment (Fig. S1A and B). These results suggest that (chemo)
radiotherapy as used in cervical cancer patients is
immunosuppressive.
Radiotherapy reduces T-cell reactivity against common
recall antigens and mitogens
PBMCs were stimulated with a pool of Influenza M1 peptides
(FLU) and with a mix of bacterial recall antigens (MRM) to test
if radiation therapy suppresses the capacity of T cells to
respond to antigenic stimulation. In 29/30 patients (96.7%) the
T-cell reactivity to FLU and MRM was strongly decreased dur-
ing and shortly after completion of EBRT when compared to
baseline (Fig. 3). Strikingly, the T-cell reactivity to MRM and
FLU remained suppressed at 6 weeks and 9 weeks after comple-
tion of EBRT. The combined data show a severe decrease in the
Figure 2. (Chemo)radiotherapy induced reduction in the absolute numbers of leukocytes and lymphocytes. (A) Time course of changes in the absolute number of leuko-
cytes and lymphocytes before (baseline) treatment and during the first 5 d of fractionized radiotherapy. (B) Time course of changes in absolute number of leukocytes and
lymphocytes before (baseline), during (15 fractions) and after (chemo)radiotherapy (3, 6 and 9 weeks after completion). Data are expressed as means § SD, p < 0.05.
Abbreviations: fract D fractions; wks D weeks.
Table 1. Clinical and tumor characteristics of patients.
N D 30
Number (percentage)








Tumor size (average) 32.8 mm (range 10–75 mm)
Treatment with
EBRTC ChTh C BT 18 (60%)
EBRTC ChTh 5 (16.7%)
EBRT 4 (13.3%)
EBRTC BT 2 (6.7%)
EBRTC HT 1 (3.3%)
Treatment for
Primary disease 18 (60%)
Adjuvant 8 (26.7%)
Recurrent disease 4 (13.3%)
For patients suffering from locally advanced cervical cancer, tumor size was mea-
sured before primary radiation therapy by magnetic resonance imaging (MRI).
Age of the patients is given in years. Abbreviations: BT, brachytherapy; ChTh,
chemotherapy; EBRT, external beam radiation therapy, FIGOD International Fed-
eration of Gynecology and Obstetrics, HT D hyperthermia.
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capacity of T cells to respond to stimulation with MRM and
FLU after 15 fractions of EBRT (p D 0.0027 for MRM and p <
0.0001 for FLU). This situation continued until 6 weeks after
termination of treatment (p D 0.0001 for MRM and p < 0.0001
for FLU) and was still retained at 9 weeks post-treatment, with
mean stimulation index of 3.71 (p D 0.0091; Fig. 3). A sub-
analysis comparing patients receiving either EBRT only or the
combination of EBRT with cisplatin, showed a decrease in T-
cell reactivity against both MRM and FLU regardless of the
type of treatment (Fig. S1C and D). Interestingly, patients
receiving EBRT only displayed higher baseline reactivity than
those receiving chemoradiotherapy which nonetheless col-
lapsed demonstrating the profound impact of EBRT on T-cell
responsiveness.
Upon analysis of individual patient data it was noticed that
four patients (ID3, ID5, ID8 and ID13) showed a high baseline
T-cell response, a less severe decrease in T-cell reactivity and a
persistent positive response during radiation therapy (ID3,
ID8) or chemoradiotherapy (ID5, ID13) (Fig. S2A). Further-
more, in six (ID16, ID17, ID20, ID21, ID27, ID29, all treated
with chemoradiation) of the 12 patients (50%) with the
extended follow-up, a restoration of the proliferative T-cell
response against FLU was noted at 6 and/or 9 weeks post-che-
moradiation (Fig. S2B). These data showed that EBRT is associ-
ated with a loss in T-cell reactivity against common recall
antigens, slowly recovering after cessation of therapy.
To gain more insight in the dynamics of T-cell reactivity during
and after (chemo)radiotherapy, we decided to study the immune-
cell composition and function of these 10 patients in more detail.
First, the T-cell responses to PHA stimulation was studied and
found to be strong for all 10 patients at baseline, with a mean stim-
ulation index of 200.6 (range 54.0–586.0). The four patients who
retained T-cell reactivity against the recall antigen FLU also
showed a strong T-cell response to PHA stimulation throughout
radiotherapy (mean stimulation index after 15 fractions was
325.75, range 121.0–446.0). For the six patients showing a chemo-
radiotherapy-induced reduction in recall antigen responsiveness,
T-cell reactivity to PHA also significantly (p D 0.03) decreased to
a mean stimulation index of 67.6 (range 15.0–123.0), albeit that
reactivity was never completely lost (data not shown).
Radiotherapy impairs the T-cell stimulatory capacity of
APC
The antigen presenting capacity of the patient’s PBMCs was
determined in a MLR.23 At baseline, the capacity of APCs to
stimulate allogeneic T cells to proliferate was strong for all
patients but a significant decrease in APC capacity was
observed upon treatment (Fig. 4), with a mean fold change in
stimulation index of 0.62 after 15 fractions, 0.56 at 3 weeks,
0.66 at 6 weeks and 0.62 at 9 weeks after treatment compared
to baseline. Two of the patients were treated with EBRT only,
and the eight other patients concurrently received cisplatin.
Nonetheless, the suppressive treatment effect on APC capacity
occurred regardless the therapy. Note, however, that the group
of EBRT only is very small. Altogether, (chemo)radiation not
only altered the number of circulating lymphocytes but also
impaired the capacity of circulating APC to stimulate allogeneic
T-cell proliferation in mixed lymphocyte reactions, shown as
the decreased T-cell responsiveness within patient’s PBMC to
recall antigens and mitogens.
Figure 4. (Chemo)radiotherapy impairs the ability of antigen presenting cells to stimulate allogeneic T cells. Antigen presenting capacity of PBMCs as determined in a
mixed lymphocyte reaction (MLR) in the blood samples from 10 patients are plotted over time. Treatment-induced changes in lymphocyte reactions as observed in the
MLR based on (A) stimulation index (S.I.), expressed as mean § SEM and (B) expressed as the fold changes (mean C SEM) of these S.I. over baseline. Time point include
baseline, after 15 fractions of EBRT and at 3, 6 and 9 weeks after completion of EBRT. p <0.05 with respect to baseline. Abbreviations: wks D weeks; fract D fractions.
Figure 3. The effect of (chemo)radiotherapy on T-cell reactivity. The response of
circulating T cells against memory response mix (MRM; black bars) and influenza
M1 protein-derived peptides (FLU; white bars) was measured in the lymphocyte
stimulation test (LST). T cell proliferation is expressed as stimulation index C stan-
dard error of the mean (SEM) and shown at different time points, including base-
line, after 15 fractions of EBRT and 3, 6 and 9 weeks after completion of EBRT. Data
were analyzed by mixed model and expressed as means C SEM. p <0.05 with
respect to baseline. Abbreviations: wks D weeks; fract D fractions.
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Suppressive myeloid cell populations are more
radioresistant than lymphocytes
The loss of T-cell reactivity and stimulatory capacity of APC
in these 10 patients was associated with changes in the
immune cell composition. After 15 fractionated doses of radi-
ation therapy a significant decrease in the percentage of circu-
lating lymphoid (CD3CCD19¡) cells, and a concomitant
increase in myeloid (CD3¡CD19¡) cell populations occurred
(p D 0.0002 and p D 0.0006, respectively). This effect on
circulating lymphoid cells (p < 0.0001) and myeloid cells
(p < 0.0001) was still present after completion of the therapy,
and was most prominent at 3 weeks after last EBRT (Fig. 5).
Six to nine weeks after completion of radiotherapy, a slight
increase of lymphoid cells and decrease of myeloid cells was
observed, but the percentages remained significantly changed
when compared to baseline. The effect on circulating lym-
phoid and myeloid cells occurred regardless the administra-
tion of cisplatin since similar kinetics in the percentages of
lymphoid cells and myeloid cells are seen in patients treated
with EBRT only (two patients) and the patients with cisplatin
C EBRT (eight patients; Fig. S3A and B). A more in-depth
analysis of the myeloid cell populations was based on of the
expression of HLA-DR, to distinguish between macrophages
or dendritic cells (DCs) (both HLA-DRC) and MDSC (HLA-
DR¡/low). In addition, the differential expression of CD14 and
CD11b within the HLA-DRC myeloid cell population was
used to identify five previously reported subpopulations.23
For all the 10 patients a significant (p D 0.009) increase in the
percentage of CD3¡CD19¡CD1a¡HLA-DRC myeloid cells
was observed after 15 fractions of radiotherapy. This effect
was stronger at 3 weeks (p < 0.0001), and the percentage of
circulating myeloid cells remained significantly elevated at
9 weeks after completion of the radiotherapy (p D 0.0005),
when compared to baseline (Fig. S4A). This effect was most
pronounced for the population of CD14CCD11bC expressing
monocytes (Fig. S4B; p D 0.0038) and was retained after com-
pletion of the treatment. Although the percentage of circulat-
ing CD3¡CD19¡CD1a¡HLA-DR¡CD14CCD15¡ monocytic
MDSC (mMDSC) were very low at baseline (average 0.11%,
range 0.02–0.31%), they increased in 9 out of the 10 patients
upon radiotherapy, with a mean percentage in mMDSCs of
0.28% (range 0.04–1.32%; data not shown). Interestingly, the
loss of T-cell reactivity against the recall antigen FLU was par-
alleled by the decrease in lymphoid cells and an increase in
subpopulations of less stimulatory or even suppressive types
of myeloid cells (Fig. S5). These data show that some myeloid
cell populations are more radioresistant than lymphocytes
and that their presence is associated an impaired T-cell
response to recall antigens as well as an impaired antigen pre-
senting cell capacity to stimulate allogeneic T cells. This sug-
gests an overall immunosuppressive effect of (chemo)
radiotherapy on systemic immunity in patients with cervical
cancer.
Figure 5. (Chemo)radiotherapy alters the relative frequencies of circulating myeloid and lymphoid cells. (A) Percentages of lymphoid cells (CD3CCD19¡) and myeloid cells
(CD3¡CD19¡) of viable cells as measured by flow cytometry. Mean percentages are shown for 10 patients with a complete follow-up at different time points, including
baseline, after 15 fractions of EBRT and at 3, 6 or 9 weeks after completion of EBRT. Percentage are expressed as mean § SD. (B) Fold changes in lymphoid and myeloid
cells over baseline. Fold changes are expressed as mean C SEM; p <0.05 with respect to baseline. Abbreviations: wks D weeks; fract D fractions.
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A specific increase in PD-1 expression by T cells upon
radiotherapy
Analysis of the T-cell populations in PBMCs showed a strong
reduction in the percentage of both CD4C and CD8C T cells in
9 of the 10 analyzed patients. However, the percentage of
CD4CCD25CCD127¡Foxp3C regulatory T cells (Treg) and
CD4CCD25CCD127¡Foxp3CCD45RA¡ activated regulatory T
cells (aTreg) were not significantly altered during treatment
(Fig. S6). We previously demonstrated that the frequency of
CD4C and CD8C T cells expressing the co-inhibitory marker
program death-1 (PD-1) was increased in cervical cancer
patients when compared to healthy controls.23 Therefore, the
expression of PD-1, cytotoxic T-lymphocyte antigen-4 (CTLA-
4) and T-cell immunoglobulin mucin-3 (TIM-3) was analyzed
to determine whether radiotherapy influences the expression of
these inhibitory markers. Although the percentage of CTLA-4
and/or TIM-3 expressing CD4C or CD8C T cells remained sim-
ilar upon treatment, we observed a high expression of PD-1 on
a minority of circulating CD4C T cells at baseline (range 5.8–
40.6%), which increased up to 2.7-fold upon radiotherapy
(range 10.8–71.4%). These higher percentages of PD-1 express-
ing CD4C T cells occurred in all patients (regardless whether
EBRT was combined with concurrent cisplatin (eight patients)
or not (two patients; Fig. S7) and remained elevated for up to
9 weeks after radiotherapy (Fig. 6A and B). A similar effect was
seen on circulating CD8C T cells, with a significant increase of
PD-1 expression 3 weeks after (chemo)radiotherapy when
compared to baseline (p D 0.002, data not shown). The increase
of PD-1 expression of CD4C T cells upon treatment was
accompanied with the decline in T-cell response against viral
(FLU) antigens (Fig. S7). Notably, compared to the other nine
Figure 6. (Chemo)radiotherapy induces CD4C T-cell suppression via PD-1. (A) Percentage of PD-1C expressing CD4C T cells for individual patients. (B) Aggregated fold
changes of percentages with respect to baseline, p <0.05 with respect to baseline. (C, D) Stimulation of five baseline PBMC samples with influenza Matrix 1 protein-
derived peptides (FLU) in vitro in the presence (white bars) or absence (black bars) of PD-1 blocking using 1 mg/mL Nivolumab. (E, F) Stimulation of three post-treatment
samples with FLU in vitro in the presence (white bars) or absence (black bars) of PD-1 blocking with 1 mg/mL Nivolumab. Displayed in (C) and (E) is the proliferation,
expressed as counts per minute (cpm), shown as mean of triplicate wells plus standard deviation after stimulation. (D, F) Cytokine IFNg production as measured within
the supernatant of the proliferation assay, with and without PD-1 blocking. Abbreviations: wks D weeks; fract D fractions; cpm D counts per minute.
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patients, patient ID29 displayed a remarkably high level of
CD4C-PD1C T cells at baseline (39%) and concurrently the
lowest T-cell reactivity in the LST, suggesting that PD-1 expres-
sion may have contributed to the insufficient immune response
upon treatment with chemoradiotherapy. We subsequently
explored whether blocking of the PD-1 signaling could improve
T-cell responses. We used the PD-1 blocking antibody Nivolu-
mab and stimulated five baseline and three post-chemoradio-
therapy PBMC samples, which were still available to us, with
autologous monocytes pulsed with a pool of FLU peptides. As a
control, non-blocked PBMCs were used. We observed higher
antigen-specific T-cell proliferation in four and increased IFNg
production in five out of the five tested baseline PBMC samples
when Nivolumab was present (Fig. 6C and D), indicating that
PD-1 expression contributed to the immune suppression in
patients with cervical cancer. Unfortunately, this effect of anti-
PD-1 was seen in only one out of the three post-chemoradio-
therapy samples; the antigen-specific IFNg production was
partly restored for patient ID5 (Fig. 6E and F). Apparently,
radiotherapy disturbs immunity via multiple other pathways,
rendering concurrent PD-1 blocking less adequate for restora-
tion of T-cell reactivity against recall antigens in this setting.
Discussion
In this study, the immunological effects of standard (chemo)
radiotherapy in patients with cervical cancer were studied.
Radiotherapy without bone marrow sparing induced a substan-
tial and long-lasting immune suppression. From the first frac-
tions onwards, a decrease in the number of circulating
lymphocytes, a decrease in T-cell reactivity to common recall
antigens and a decrease in the capacity of APC to stimulate T-
cell responses were found. Immune reactivity slowly recovered
after cessation of therapy with only half of the patients
responding 9 weeks after therapy. These effects on peripheral
immune cells, T-cell function and APC capacity were similar
for patients treated with radiation therapy alone or with con-
comitant chemotherapy, confirming an earlier report showing
that radiotherapy alone and radiotherapy with concomitant cis-
platin decreased the absolute number of all lymphocyte subsets
and decreased PHA-induced T-cell proliferation.24
Chemoradiotherapy was also reported to be immune sup-
pressive in patients with HPV-related oropharyngeal cancer.25
A decrease in CD4C and CD8C T cells, an increase of MDSCs
and an unfavorable CD8C/Treg ratio upon radiation treatment
was seen. Furthermore, an upregulation of PD-1 expression on
CD4C T cells was noted, which occurred 3 weeks after comple-
tion of therapy and remained elevated for up to 1 y following
therapy.25 Although the radiation field in this patient group
contains less active bone marrow, the immunosuppressive
effects were long lasting (up to 1 y after treatment), indicating
the direct effect of radiotherapy on the peripheral blood cells.
PD-1 is a key immune checkpoint protein expressed on acti-
vated and exhausted T cells, which leads to the suppression of
T-cell activity through interaction with its ligand PD-L1. We
also observed elevated PD-1 expression on CD4C T cells during
and following radiotherapy and showed that this was associated
with the impaired T-cell reactivity against FLU and impaired
ability of APCs to stimulate allogeneic T cells. Together, this is
strongly suggestive for radiotherapy induced immune suppres-
sion. There are a number of clinically available antibodies to
block PD-1 signaling (e.g., Nivolumab, Pembrolizumab and
Lambrolizumab). We hypothesized that PD-1 blockade could
reverse radiotherapy-induced immune suppression. While our
in vitro experiments in blocking PD-1 in PBMC samples iso-
lated before radiotherapy provide further support for targeting
PD-1 and its ligand in cervical cancer, this was hardly the case
after the initiation of radiotherapy. PD-1 blocking in patients
treated with (chemo)radiotherapy partly restored cytokine pro-
duction but not proliferation of antigen-stimulated T cells.
These data do not support a combination of the (chemo)radio-
therapy together with PD-1/PD-L1 blockade to obtain more
clinical benefit.
An increase in circulating MDSCs and myeloid cells upon
(chemo)radiotherapy and a change in capacity of circulating
APCs, reflected in a subverted reactivity of T cells to recall anti-
gen stimulation as well as a lower response of allogeneic T cells
to become activated was observed after completion of radio-
therapy. This suggests that the loss of T-cell reactivity and stim-
ulatory capacity of APC may also be caused by changes in the
immune cell composition, in favor of (suppressive) myeloid
cell populations.
Our results indicate that it will be a considerable challenge to
establish the optimal delivery and dosing strategies when com-
bining radiotherapy and immunotherapy before combinations
hereof can successfully be applied to cervical cancer patients. In
pre-clinical models, it was demonstrated that a radiation-based
therapy (an in situ ablation treatment based on intra-tumor-
al224Ra-loaded wires that release its daughter atoms) inhibited
breast, colon and lung tumor growth by stimulating anti-tumor
immunity. It was suggested that combinations of local ablation
treatments and immunotherapy could further augment power-
ful anti-tumor immunity.26 However, translation of radio-
immunotherapy to the clinic requires careful consideration of
the radiation dose and fractionation for both the tumor and
organs at risk, particularly the bone marrow. Hematologic tox-
icity, including lymphopenia, is frequently noted in women
undergoing pelvic radiotherapy for cervical cancer, because
approximately 40% of the active bone marrow is located in the
pelvic region, and T cells constantly circulate though this irra-
diation field.27,28 The extreme sensitivity of active pelvic bone
marrow was recently demonstrated by McGuire et al. using
[18F]Fluorothymidine (FLT) imaging using positron emission
tomography (FLT-PET) to identify active bone marrow before,
during and after radiotherapy.29 As little as a radiation dose of
4–5 Gy resulted in an approximately 50% decrease in FLT
uptake and the suppression of bone marrow activity was mea-
surable up to 1 y after radiotherapy, especially in pelvic cancer
patients receiving radiation doses of more than 35 Gy.29 Based
on empirical experience, the use of daily fractions of 2 Gy to a
total dose of approximately 46–50 Gy has evolved as a standard
radiotherapy approach to control microscopic disease for most
tumor types including cervical cancer. It is possible that differ-
ent treatment regimens, depending on fractioning, dosing and
delivery may have different effects on antitumor immunity. In
the setting of cervical cancer, an immune enhancing effect was
seen in the tumor-draining lymph nodes of patients undergo-
ing low-dose radiation (total dose 39.6 Gy), while an
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immunosuppressive effect was observed in patients treated with
high-dose radiation (total dose 50 Gy). Although dose differen-
ces were only minor, lower-dose radiation was associated with
an increase in the anti-tumor Th1 and cytotoxic T-cell subsets,
while a lower frequency of Tregs was noticed when compared
to higher-dose radiation therapy.30 Furthermore, local low-
dose gamma irradiation (2 Gy) caused normalization of aber-
rant vasculature and increased recruitment of tumor-specific T
cells into human pancreatic tumors, by the polarization of M2-
like toward M1-like macrophages.31
This underlines again the importance of further characteri-
zation of the effect of radiotherapy on the immune system. To
reduce the incidence and severity of hematologic toxicity, the
use of techniques that limit pelvic bone marrow irradiation is
of interest.32,33 Especially bone marrow sparing (BMS) intensity
modulated radiotherapy (IMRT) is a technique that could
reduce the volume of bone marrow receiving high dosages,
while maintaining target coverage, resulting in less hematologic
toxicity,29 and potentially limit the suppressive effect on lym-
phoid populations and immune responses. Until now, there is
no clear evidence for an optimal radiation dose fractionation
schedule based on clinical data to elicit antitumor immune
responses, and there is a lack of (randomized) studies compar-
ing radiation regimens (with or without bone marrow sparing)
for their ability to synergize with immunotherapy. The optimal
dose and fractionation schedule should cause sufficient cyto-
toxic effects for tumor eradication, while reducing myeloid cell
associated suppressive effects and foster lymphoid cell popula-
tions and effective immune responses. As peripheral blood lym-
phocyte count and lymphocyte subsets have shown to be
independent predictors of survival and tumor regression in cer-
vical cancer patients treated with concurrent chemoradia-
tion,9,10 such immunological markers could be used to select
the optimal (combination) treatment schedule for the patient
that benefits most.
There were some limitations of this study. Our analyses
were limited to the systemic immunity, rather than direct
examination of the intra-tumoral cell composition itself. It
remains to be established whether (chemo)radiotherapy-
induced alterations in circulating immune cells also occurs at
the tumor site. It has been shown in head and neck cancer
patients that tumor infiltrating T cells have a higher expres-
sion of PD-1 compared to circulating T cells.34 In addition,
cryopreservation may cause downregulation of PD-1 and PD-
L1 expression on PBMCs. This implies that our findings on
radiotherapy-induced increased PD-1 expression on CD4C T
cells may underestimate the effect of radiotherapy on the
tumor and its microenvironment. Another limitation is the
relatively small number of patients participating in this trial
(N D 30) and the variation in the amount of blood samples
provided by patients. Due to clinical conditions and disease
burden, motivating patients to donate blood was difficult. A
further limitation is the heterogeneity in the participating
patients. Differences in FIGO stage, treatment (adjuvant ver-
sus primary) and clinical performance status, made it difficult
to study potential interesting differences between patient
groups. In addition, there was a high variation in treatment
modalities. Although every patient was treated with high dose
EBRT without bone marrow sparing, there were different
additional treatment regimens including concurrent chemo-
therapy, hyperthermia and/or brachytherapy.
In conclusion, our data show that standard non-BMS radio-
therapy affects circulating immune cells and immune
responses, causing immune suppression in patients with cervi-
cal cancer. Relevant mechanisms underlying this (chemo)radio-
therapy-induced immunosuppression include decrease in
lymphoid cells, decrease of APC function, increase of different
subsets of myeloid cells and PD-1 upregulation on T cells. Stud-
ies on the immunological effects of BMS radiotherapy should
be made, in order to determine whether alternative treatments




The Medical Ethics Committees of the Leiden University Medi-
cal Center (LUMC) and the Netherlands Cancer Institute-
Antoni van Leeuwenhoek hospital (NKI-AvL) formally
approved the protocol of this study. The study was conducted
according to the Dutch Act on Medical Research involving
Human Subjects (WMO) and was registered under number
NL36829.058.11. Written informed consent was obtained from
all patients before study inclusion and participation. All partici-
pating patients were acknowledged that they were fully anony-
mized and cannot be identified via the paper.
Patients and treatments
This observational study was performed at the gynecology clin-
ics of the LUMC and the NKI-AvL from October 2011 to
December 2014. Thirty patients with invasive cervical cancer
(FIGO stage IB1 to IV35) with an indication for external beam
radiation therapy (EBRT) were recruited for participation.
Additionally, the eligibility of patients required all of the fol-
lowing criteria: mentally competent patients of 18 y and older,
no other active malignancy than cervical cancer, no indication
of active infectious disease such as HIV and hepatitis B, and no
medical condition that may interfere with the study objectives.
Radiotherapy was used as primary treatment for locally
advanced disease (FIGO stages IB2-IIIB, or lymph node posi-
tive), in combination with concurrent cisplatin chemotherapy
and brachytherapy (BT). As adjuvant therapy after radical hys-
terectomy and pelvic lymphadenectomy for early stage disease,
radiotherapy was applied in case of high-risk early stage disease
with two or three unfavorable tumor characteristics.36-39 Unfa-
vorable tumor characteristics included tumor diameter exceed-
ing 40 mm, tumor depth more or equal to 15 mm and
lymphovascular space involvement (LVSI). Patients with two
or more tumor-positive lymph nodes, parametrial infiltration,
or tumor-positive surgical margins were treated with radiother-
apy and concurrent cisplatin chemotherapy. Patients suffering
from recurrent cervical cancer with only surgical treatment in
history were treated with EBRT in combination with chemo-
therapy, with or without BT. Patients with a contra-indication
for cisplatin treatment were treated with 5 weekly courses of
deep tissue hyperthermia.
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All treatments were performed in accordance with the
guidelines of the radiotherapy departments of the participating
hospitals. EBRT was delivered in 23 fractions of 2 Gy (total 46
Gy) or an equivalent dose given in fractions of 1.8 Gy; 5 times a
week. An EBRT boost was given in patients with PET-CT sus-
pected lymph node metastases, aiming for a total dose of
60 Gy, taking the BT dose contribution into account. Standard
EBRT was delivered using either conventional three-dimen-
sional (3D-CRT) or intensity modulated radiation therapy
(IMRT) without constraints for bone marrow sparing. Concur-
rent chemotherapy consisted of 5 or 6 weekly cycles of intrave-
nous cisplatin (40 mg/m2 per cycle). Dose adjustments,
omissions and delays were implemented as the standard intra-
venous cisplatin administration protocol of the institutes.
Upon completion of EBRT, MRI-guided intracavitary alone or
combined interstitial–intracavitary high dose rate BT was
administered in three or four fractions of 7 Gy.40 The dose rate
and fractionation was performed according to the department
policy, aiming at an equivalent dose in 2 Gy fractions (EQD2
dose) of at least 80–85 Gy in high risk-clinical target volume
(HR-CTV) according to the Groupe Europeen de Curietherapie
(GEC) and the European Society for Radiotherapy & Oncology
(ESTRO) guidelines.41 The aim was to maintain the overall
treatment time within 7 weeks.
Blood sampling and follow-up
Venous blood sampling for routine leukocyte differential count
analysis took place daily during the first week of EBRT. These
samples were analyzed for leukocyte differentiation at the routine
laboratories of LUMC or NKI-AvL. Additionally, a full blood
count and blood sampling for immunomonitoring were per-
formed before start of radiotherapy (baseline), after 15 fractions
of EBRT (midway) and at 3 weeks after completion of EBRT.
Analysis of the data obtained in the first 15 patients at 3 weeks
after therapy showed substantial decreases in lymphocyte counts
and an impaired capacity of peripheral blood mononuclear cells
(PBMCs) to respond to antigenic stimulation. Therefore, the pro-
tocol was amended to allow extra blood samples for immunolog-
ical analysis at 6 and 9 weeks after completion of radiation
therapy for the subsequent 15 patients. Twelve patients of the
second group consented for these additional blood draws at 6
and 9 weeks. Fig. 1 shows treatment schedules in detail, with
exact intervals between treatments and blood samples.
Immunomonitoring
Venous blood samples for immunomonitoring were taken in 6
heparinized tubes of 9 mL to isolate PBMCs and in one 9 mL
clot activator tube to obtain serum. Blood samples were trans-
ported at room temperature and PBMCs were isolated by Ficoll
gradient centrifugation within 6 h. Part of these freshly
obtained PBMCs was used for the lymphocyte stimulation test
(LST). The remaining cells were cryopreserved in 90% fetal calf
serum (PAA Laboratories, Pashing, Austria) and 10% DSMO
at a concentration of 7 to 12 million cells per vial in a total vol-
ume of 1 mL using a mister Frosty’s freezing container (Nal-
gene). Upon cryopreservation the vials were stored in the vapor
phase of the liquid nitrogen until further use. Immunological
assays were performed and analyzed under blinding for clinical
parameters of the participating patients.
T-cell proliferation assays
The proliferative response to the memory response mix (MRM)
and influenza matrix 1 protein-derived peptides (FLU)40 was
determined using freshly isolated PBMCs that were subjected
to the LST as described previously.23,42 In short, eight replicate
wells with 1.5£105 cells per well were stimulated for 6 d with
the indicated antigens (10 mg/mL), after which 50 mL superna-
tant per well was harvested, pooled for the eight similar wells
and stored at ¡20C for cytokine analysis. The cells were
pulsed with 10 mCi/mL [3H]-thymidine (PerkinElmer, the
Netherlands). The negative control consisted of cells in
medium (Iscove’s Modified Dulbecco’s Medium, IMDM
(Lonza) plus 10% human AB serum (Life Technologies)) only.
A positive response was defined as a stimulation index (S.I.) of
at least 3 under the condition that six out of eight wells dis-
played values above the cut off value, which was defined as the
mean value of the cells in medium only plus 3£ standard devia-
tion (SD).
The capacity to respond to Phytohemagglutinin (PHA) was
studied using cryopreserved PBMCs.23 Cells were thawed and
tested in a 3-d proliferation assay with the minor alteration
that 50,000 cells per well (in quadruplicate) were incubated in
medium (IMDM) or stimulated with 0.25 mg/mL PHA (Murex
Biotech HA16). At day 2, 100 mL supernatant per well was har-
vested for cytokine analysis, and cells were subjected to [3H]-
thymidine (50 mL/well of 10 mCi/mL) for an additional 16–
20 h. A positive response was defined as an S.I. of 3 or higher.
Antigen presenting capacity assay
The antigen presenting capacity of the patient’s PBMCs was
determined in a mixed lymphocyte reaction (MLR).23 PBMCs
were thawed in IMDM plus 10% fetal calf serum and 30 mg/mL
DNase (Sigma-Aldrich, St. Louis, USA), pelleted and suspended
in IMDM plus 10% human AB serum. Then, irradiated (3,000
rad) to prevent proliferation, washed, suspended in IMDM
plus 10% human AB serum and plated at 1£105 cells per well
(in quadruplicate). Third party PBMCs of two donors were
added to determine their proliferative capacity upon encoun-
tering the irradiated patients’ APCs. Third party PBMCs only
as well as irradiated patients PBMCs only were used as negative
controls. At day 6, 100 mL supernatant per well was harvested
for cytokine analysis, and the cells were subjected to [3H]-thy-
midine (50 mL/well of 10 mCi/mL) for an additional 16–20 h.
A positive response was defined as an S.I. of at least 3.
Cytokine analysis
The supernatants harvested in the proliferation and MLR
assays were subjected to a flow cytometer based cytokine bead
array (CBA, human Th1/Th2 kit, BD), which was conducted
according to the manufacturer’s instructions and as reported
earlier.42 The cytokine panel consisted of IFNg, TNF-a, IL-10,
IL-5, IL-4 and IL-2. A positive response was defined as a cyto-
kine concentration above the detection limit as indicated by the
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manufacturer, which was 20 pg/mL for each cytokine. Treat-
ment-related change in cytokine production was defined as a
cytokine concentration above the cut-off value and a 3-fold
increase or decrease above the baseline sample (pre-radiothera-
peutic treatment).
Phenotyping of PBMCs
The PBMC samples isolated at different time points were phe-
notyped as described earlier by using three sets of 10–13 cell
surface markers to identify immune cell subsets and the expres-
sion of co-inhibitory molecules by flow cytometry.23
The myeloid set consists of CD3-HV450 (Clone UCHT1;
BD Biosciences), CD1a-FITC (Clone HI149; BD Biosciences),
CD11b-PE (Clone D12; BD Biosciences), CD11c-BV650 (Clone
B-ly6; BD Biosciences), CD14-AF700 (Clone M5E2; BD Bio-
sciences), CD15-PE-CF594 (Clone W6D3; BD Biosciences),
CD19-BV605 (Clone SJ25C1; BD Biosciences), CD33-PE-Cy7
(Clone P67.6; BD Biosciences), CD56-PerCP-Cy5.5 (Clone
HCD56; BioLegend), CD163-APC (Clone 215927; R&D Sys-
tems), CD206-APC-Cy7 (Clone 15–2; BioLegend) and HLA-
DR-V500 (Clone L243; BD Biosciences).
The inhibitory set consists of CD3-HV450 (Clone UCHT1;
BD Biosciences), and CD4C-PE-CF594 (Clone RPA-T4; BD Bio-
sciences), CD8C-APC-Cy7 (Clone SK1; BD Biosciences), CD56-
AF700 (Clone B159; BD Biosciences), CD94-FITC (Clone
131412; R&D Systems), CD152-PE-Cy5 (anti-CTLA-4, Clone
BN13; BD Biosciences), CD279-PE-Cy7 (anti-PD-1, Clone
EH12.2H7; BioLegend), TIM-3-BV605 (Clone F38.2E2; BioLe-
gend) and CD159a-PE (NKG2a, Clone Z199; Beckman Coulter).
The regulatory T-cell set consists of CD3-HV500 (Clone
UCHT1; BD Biosciences), and CD4C-AF700 (Clone RPA-T4;
BD Biosciences), CD8C-PerCP-Cy5.5 (Clone SK1; BD Bio-
sciences), CD25-PE-Cy7 (Clone 2A3; BD Biosciences), CD127-
BV650 (Clone HIL-7R-M21; BD Biosciences), CD45RA-APC-
H7 (Clone HI100; BD Biosciences), CD152-BV421 (CTLA-4,
Clone BNI3, BD Biosciences); FoxP3-PE-CF594 (Clone 259D/
C7; BD Biosciences), Helios-APC (Clone 22F6; BioLegend) and
Ki67-FITC (Clone 20Raj1; eBioscience).43
The cryopreserved PBMCs were thawed and first subjected
to live-dead marker (Yellow amino reactive dye (ARD); dilu-
tion 1:800) incubation for 20 min at room temperature in
100 mL/well. Then, the cells were pelleted and suspended in
phosphate buffered saline (PBS), washed and supplemented
with 0.5% bovine serum albumin (BSA, Sigma) and 10% FCS
for an incubation of 10 min on ice (4C and in the dark) to pre-
vent non-specific antibody binding to free Fc-receptors on the
cells. Subsequently, the cells were centrifuged, washed and sus-
pended in the antibody mixtures described above and incu-
bated in the dark for 30 min on ice. Finally, the cells were
washed twice with PBS/0.5% BSA and suspended in 1% para-
formaldehyde (LUMC Pharmacy). For the regulatory T-cell
staining, following the Yellow ARD incubation and blocking
step, cells were stained for surface markers as described above,
washed twice with PBS/0.5% BSA and subsequently fixated in
transcription factor fixation and permeabilized by buffer (BD)
and intranuclear stained with the antibodies CD152, FoxP3,
Helios and Ki67 (diluted in permeabilization and washing
buffer (BD)) for 40–50 min on ice. Cells were finally suspended
in 1% paraformaldehyde and assessed within 24 h while keep-
ing them in the dark at 4C.
Flow cytometry
Acquisition on the BD Fortessa flow cytometers was performed
within 24 h after staining of the cells was finished. Analysis was
performed using DIVA software (BD Biosciences, version 6.2).
PD-1 blocking and stimulation of PBMC in vitro
Thawed autologous monocytes (1–4 £ 106 cells/mL) were
adhered to the bottom of the wells in a 96-wells plate in X-vivo
15 medium (Lonza) during 2 h incubation at 37C, 5% CO2 in
a humidified incubator. The wells were subsequently gently
washed to remove non-adherent responder cells (which were
centrifuged and stored in a 15 mL tube in IMDM with 10%
human AB serum and rested overnight in the incubator) and
the adhered monocytes were replenished in 75 mL X-vivo 15
medium with 800 U/mL granulocyte macrophage colony-stim-
ulating factor (GM-CSF) and incubated for 5 h in the incuba-
tor. Then, the monocytes were overnight loaded in triplicate
wells with 75 mL of the FLU peptide pool (at a concentration of
5 mL/mL) diluted in X-vivo 15 medium. Medium only served
as a negative control. The next day, responder cells (50,000–
100,000 cells/well) were added as well as the anti-PD-1 anti-
body Nivolumab (final concentration of 1 mg/mL). After 5 d of
incubation, 50 mL supernatant per well was harvested and
stored at ¡20C for cytokine analysis. The cells were pulsed
with [3H]-thymidine (PerkinElmer, the Netherlands), and fil-
ters were counted using a bplate counter.
Laboratory environment
Immunomonitoring of patient’s PBMCs was performed in the
laboratory of the department of Medical Oncology at LUMC
that operates under research conditions, following standard
operating procedures (SOPs) and using trained personnel. The
authors acknowledge the reporting of results from T-cell assays
according to the minimal information about T-cell assays
(MIATA). Definitions of positive responses were pre-estab-
lished. This laboratory has been audited both internally and
externally, according to the reflection paper for laboratories
that perform immunomonitoring.44 The laboratory has partici-
pated in all proficiency panels of the CIMT Immunoguiding
Program (CIP; http://www.cimt.eu/workgroups/cip/) as well as
many of the proficiency panels of the USA-based Cancer
Immunotherapy Consortium (CIC of the Cancer Research
Institute), whose aim is to harmonize reporting and assays used
for immunomonitoring and to validate SOPs.
Statistical interpretation
The repeated measured immune responses of patients were
analyzed with a mixed model analysis of variance with fixed
factors time, if feasible chemotherapy and chemotherapy by
time, random factor subject. Contrasts calculated within the
model included: different time points, with or without chemo-
therapeutic treatment. The fold change in MRM and FLU,
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absolute shift in lymphoid and myeloid cells, and PD-1 express-
ing CD4C T cells were analyzed with a repeated measures
regression analysis with a compound structure covariance
structure and time as repeated factor within each subject. Anal-
ysis results per variable are generated with estimates of the dif-
ference of the different contrasts and a back transformed
estimate of the difference in percentage for log transformed
parameters, 95% confidence intervals (in percentage for log-
transformed parameters) and least square means (LSM, geo-
metric means for log transformed parameters), and a p-value of
the contrasts. A p-value < 0.05 was considered statistically sig-
nificant. All calculations and statistical analysis were performed
using SAS for Windows V9.4 (SAS Institute, Inc., Cary, NC,
USA)
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